The development of therapeutic treatments is a challenging process linked to understanding mechanisms that underly human disorders. Finding the relevant biological model has been a limiting process so far. The development of induced pluripotent stem cell (iPSC) technology has revolutionized the way we study complex disorders. iPSCs offer a unique in vitro platform for generating large quantities of cells for disease modeling, drug screening, and ultimately cell-based therapy. By combining such a platform with CRISPR-Cas9 gene editing technology, Horizon unlocks the potential to produce engineered iPSCs for a wide range of tissues and diseases.
Leveraging more than a decade of cell line engineering experience and with its optimal workflows, Horizon is able to deploy a highly efficient and highly scalable iPSC gene-editing platform to offer a wide range of cell line engineering services ranging from:
Here, we demonstrate Horizon’s efficient gene editing platform and capabilities to edit complex pluripotent stem cells for disease modeling.